• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

94例复发性和难治性艰难梭菌感染患者采用保留灌肠单次至多次粪便微生物群移植的结果及长期随访

The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema.

作者信息

Lee C H, Belanger J E, Kassam Z, Smieja M, Higgins D, Broukhanski G, Kim P T

机构信息

Department of Pathology and Molecular Medicine, McMaster University, St Joseph's Healthcare, 50 Charlton Avenue East, 424 Luke Wing, Hamilton, ON, L8N 4A6, Canada,

出版信息

Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1425-8. doi: 10.1007/s10096-014-2088-9. Epub 2014 Mar 14.

DOI:10.1007/s10096-014-2088-9
PMID:24627239
Abstract

Clostridium difficile infection (CDI) is one of the most frequent causes of healthcare-associated infections, and its rates are also increasing in the community. The management of CDI has become a major challenge, given growing rates of recurrences and failures with standard antibiotic therapy. Mounting evidence suggests that fecal microbiota transplantation (FMT) may be effective; however, as there is a paucity of data with regard to repeat FMT for primary non-response to this treatment, this study examined the outcome of multiple FMTs for recurrent CDI. Case records were reviewed for 94 patients who underwent FMT via retention enema for recurrent or refractory CDI during the period 2008-2012. Demographic information, treatment data, and clinical resolution rates were examined for single FMT and cumulative resolution was assessed for multiple FMTs in the context of ongoing symptoms. The cumulative clinical resolution following four or more FMTs was 86%. When antibiotic therapy was used between FMTs, the clinical resolution rate increased to 92%. There were no reported adverse events and no patients who were cured with FMT had further episodes of CDI at 6-24 months follow-up. Multiple FMTs administered through enemas is an effective, safe, and simple therapy for the management of recurrent or refractory CDI.

摘要

艰难梭菌感染(CDI)是医疗保健相关感染最常见的病因之一,其在社区中的发病率也在上升。鉴于标准抗生素治疗的复发率和失败率不断增加,CDI的管理已成为一项重大挑战。越来越多的证据表明,粪便微生物群移植(FMT)可能有效;然而,由于针对该治疗原发性无反应的重复FMT数据匮乏,本研究探讨了多次FMT治疗复发性CDI的结果。回顾了2008年至2012年期间94例因复发性或难治性CDI通过保留灌肠接受FMT的患者的病例记录。检查了单次FMT的人口统计学信息、治疗数据和临床缓解率,并在持续存在症状的情况下评估了多次FMT的累积缓解率。四次或更多次FMT后的累积临床缓解率为86%。当在FMT之间使用抗生素治疗时,临床缓解率提高到92%。没有报告不良事件,并且在6至24个月的随访中,接受FMT治愈的患者没有再次出现CDI发作。通过灌肠进行多次FMT是治疗复发性或难治性CDI的一种有效、安全且简单的疗法。

相似文献

1
The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema.94例复发性和难治性艰难梭菌感染患者采用保留灌肠单次至多次粪便微生物群移植的结果及长期随访
Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1425-8. doi: 10.1007/s10096-014-2088-9. Epub 2014 Mar 14.
2
Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure.粪菌移植治疗复发性或难治性艰难梭菌感染的长期耐久性和安全性:有无抗生素暴露的比较。
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1731-1735. doi: 10.1007/s10096-019-03602-2. Epub 2019 Jun 5.
3
Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection.结肠镜下粪菌移植治疗复发和难治性社区获得性及医院获得性艰难梭菌感染的疗效、安全性和患者满意度。
Can J Gastroenterol Hepatol. 2014 Sep;28(8):434-8. doi: 10.1155/2014/695029. Epub 2014 Jul 11.
4
Clinical outcomes after faecal microbiota transplant by retention enema in both immunocompetent and immunocompromised patients with recurrent Clostridioides difficile infections at an academic medical centre.在学术医疗中心,对复发性艰难梭菌感染的免疫功能正常和免疫功能低下患者,采用保留灌肠法进行粪便微生物群移植的临床结果。
J Hosp Infect. 2020 Dec;106(4):643-648. doi: 10.1016/j.jhin.2020.09.027. Epub 2020 Sep 28.
5
Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.复发性艰难梭菌感染粪菌移植后革兰氏阴性菌属种类变化和抗菌药物敏感性
mSphere. 2020 Oct 14;5(5):e00853-20. doi: 10.1128/mSphere.00853-20.
6
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection.用于复发性艰难梭菌感染的口服、冷冻粪便微生物群移植(FMT)胶囊。
BMC Med. 2016 Sep 9;14(1):134. doi: 10.1186/s12916-016-0680-9.
7
Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.粪便微生物群移植成功治疗艰难梭菌感染
J Physiol Pharmacol. 2016 Dec;67(6):859-866.
8
Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.粪便微生物群移植治疗复发性肠道艰难梭菌感染 - 十年单中心经验。
Cas Lek Cesk. 2022 Summer;161(3-4):126-130.
9
Fecal Microbiota Transplantation for Refractory and Recurrent Infection: A Case Series of Nine Patients.粪便微生物群移植治疗难治性和复发性感染:9例患者的病例系列
Korean J Gastroenterol. 2017 Apr 25;69(4):226-231. doi: 10.4166/kjg.2017.69.4.226.
10
Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.粪便微生物移植增加复发性艰难梭菌患者结肠中的 IL-25 并抑制组织炎症。
mSphere. 2021 Oct 27;6(5):e0066921. doi: 10.1128/mSphere.00669-21.

引用本文的文献

1
A review of engraftment assessments following fecal microbiota transplant.粪便微生物群移植后植入评估的综述。
Gut Microbes. 2025 Dec;17(1):2525478. doi: 10.1080/19490976.2025.2525478. Epub 2025 Jul 2.
2
The Role of Fecal Microbiota Transplantation in IBD.粪便微生物群移植在炎症性肠病中的作用
Microorganisms. 2024 Aug 23;12(9):1755. doi: 10.3390/microorganisms12091755.
3
Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus.粪便微生物群移植:2型糖尿病的一种前瞻性治疗方法。

本文引用的文献

1
Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.粪菌移植治疗艰难梭菌感染:系统评价和荟萃分析。
Am J Gastroenterol. 2013 Apr;108(4):500-8. doi: 10.1038/ajg.2013.59. Epub 2013 Mar 19.
2
Duodenal infusion of donor feces for recurrent Clostridium difficile.经十二指肠输注供体粪便治疗复发性艰难梭菌感染。
N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
3
Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series.
Diabetes Metab Syndr Obes. 2024 Feb 8;17:647-659. doi: 10.2147/DMSO.S447784. eCollection 2024.
4
Fecal Microbiota Transplant in Severe and Non-Severe Infection. Is There a Role of FMT in Primary Severe CDI?粪便微生物群移植治疗重度和非重度感染。粪便微生物群移植在原发性重度艰难梭菌感染中是否起作用?
J Clin Med. 2021 Dec 13;10(24):5822. doi: 10.3390/jcm10245822.
5
Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review.异基因造血干细胞移植受者中针对碳青霉烯类耐药肠杆菌科定植的串联粪便微生物移植周期:一例病例报告及文献复习。
Eur J Med Res. 2021 Apr 28;26(1):37. doi: 10.1186/s40001-021-00508-8.
6
Infection, Still a Long Way to Go.感染,仍有很长的路要走。
J Clin Med. 2021 Jan 20;10(3):389. doi: 10.3390/jcm10030389.
7
Faecal microbiota transplantation for recurrent infection: An updated systematic review and meta-analysis.粪便微生物群移植治疗复发性感染:一项更新的系统评价和荟萃分析。
EClinicalMedicine. 2020 Nov 23;29-30:100642. doi: 10.1016/j.eclinm.2020.100642. eCollection 2020 Dec.
8
A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group.粪便银行用于粪便微生物群移植的标准化模型:多学科 UEG 工作组的共识报告。
United European Gastroenterol J. 2021 Mar;9(2):229-247. doi: 10.1177/2050640620967898. Epub 2021 Mar 9.
9
Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy.粪菌移植和局部 5-氨基水杨酸治疗后活动期左半结肠炎患者的肠道微生物组变化。
Cells. 2020 Oct 13;9(10):2283. doi: 10.3390/cells9102283.
10
Of men in mice: the development and application of a humanized gnotobiotic mouse model for microbiome therapeutics.在雄性小鼠中:用于微生物组治疗的人源化无菌小鼠模型的开发和应用。
Exp Mol Med. 2020 Sep;52(9):1383-1396. doi: 10.1038/s12276-020-0473-2. Epub 2020 Sep 10.
粪便微生物群移植治疗复发性艰难梭菌感染:病例系列报告。
Anaerobe. 2013 Feb;19:22-6. doi: 10.1016/j.anaerobe.2012.11.004. Epub 2012 Nov 23.
4
Burden of Clostridium difficile on the healthcare system.艰难梭菌对医疗体系的负担。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S88-92. doi: 10.1093/cid/cis335.
5
Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.结肠镜粪菌移植治疗复发性艰难梭菌感染的长期随访。
Am J Gastroenterol. 2012 Jul;107(7):1079-87. doi: 10.1038/ajg.2012.60. Epub 2012 Mar 27.
6
Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection.通过保留灌肠进行粪便移植治疗难治性或复发性艰难梭菌感染。
Arch Intern Med. 2012 Jan 23;172(2):191-3. doi: 10.1001/archinte.172.2.191.
7
Modified multiple-locus variable-number tandem-repeat analysis for rapid identification and typing of Clostridium difficile during institutional outbreaks.改良多位点可变数目串联重复分析在医院暴发期间快速鉴定和分型艰难梭菌。
J Clin Microbiol. 2011 May;49(5):1983-6. doi: 10.1128/JCM.02359-10. Epub 2011 Mar 16.
8
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).艰难梭菌感染临床实践指南:美国医疗保健流行病学学会(SHEA)和美国传染病学会(IDSA)2010 年更新版。
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55. doi: 10.1086/651706.
9
Clostridium difficile--more difficult than ever.艰难梭菌——比以往任何时候都更难对付。
N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500.
10
Costs of nosocomial Clostridium difficile-associated diarrhoea.医院内艰难梭菌相关性腹泻的成本。
J Hosp Infect. 2008 Sep;70(1):15-20. doi: 10.1016/j.jhin.2008.05.004. Epub 2008 Jul 7.